TERN
Terns Pharmaceuticals, Inc.
$52.95
+0.00 (+0.00%)
At close · May 7
Market Cap
$6.12B
Shares
115,521,157
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$52.95
Open$52.95
Day$52.95–52.95
52W$2.66–53.19
Avg vol 30d6.2M
Short int5.5M · 4.8% float · 1.5d
Short vol35%
Last earningsJan 9, 2026
DataFeb 2021–May 2026
Filing10-K · Mar 30
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+86% above
+
Price vs 50-day avg
+6% above
−
RSI (14)
74 · overbought
−
MACD trend
negative
+
52-week position
100% · near high
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $50 › 200d $28 — 50d above 200d
+
Institutional flow
+30% holders QoQ · +134 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
4.79% of float · ▼ -31.3% MoM · 1.5 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
324 holders — near 3-yr high, broad support
Fundamentals
Fair
−
Revenue growth
−100% Y/Y
+
EPS growth
+8% Y/Y
−
Free cash flow
$-82.2M
+
Balance sheet
net cash $524.7M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Mar 30, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+86% above
Bullish
Price vs 50-day avg
+6% above
Bullish
RSI (14)
74 · overbought
Bearish
MACD trend
negative
Bearish
52-week position
100% · near high
Bullish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $50 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+30% holders QoQ · +134 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.79% of float · ▼ -31.3% MoM · 1.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
324 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $53 · 100%
52-wk high $53
vs 200-day avg +86%
vs 50-day avg +6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TERN
this stock
Terns Pharmaceuticals, Inc.
|
$6.12B | +31.1% | — | — | 4.8% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TERN | +0.1% | +0.7% | +160.8% | +0.1% | +31.1% |
| SPY | +1.8% | +7.6% | +7.1% | +1.8% | +7.3% |
| vs SPY | -1.8% | -6.9% | +153.8% | -1.8% | +23.8% |